Multiple Sclerosis

A new technique could aid patients recovering from spinal cord injuries and disorders affecting spinal cord function, according to researchers at Vanderbilt University.

A team of researchers has pinpointed a small molecule responsible for nerve cell damage and other symptoms tied to neurological diseases, including multiple sclerosis (MS).

The University of Southern California is developing a brain model that can pave the way for nanotechnology treatment development for multiple sclerosis and other neurological disorders.

Over the past 7 years, multiple sclerosis (MS) care costs rose 60% and were driven by common MS sequelae, according to new research.

Regional damage in the brain could be the main contributing factor to fatigue, a symptom of multiple sclerosis.

Many patients with multiple sclerosis have numerous comorbid chronic conditions that worsen mental health and increase mortality.

Although tumor necrosis factor inhibitors have dramatically improved management strategies for autoimmune disorders such as rheumatoid arthritis and inflammatory bowel disease, the biologic agents also pose a number of significant side effects that physicians must consider.

Human embryonic stem cells are a potentially viable treatment option for multiple sclerosis.

MRI technology can allow scientists to assess the development of depression and treatment responses over time in multiple sclerosis patients.

European regulators recently approved alemtuzumab to treat active relapsing-remitting multiple sclerosis, but the US Food and Drug Administration denied the drug for that indication last year.

Researchers in Saint Louis are examining the ways in which a drug already approved for multiple sclerosis could ease some of the pain associated with chemotherapy for cancer patients.

A more effective way to track the early progression of multiple sclerosis has been developed, according to research published online in Radiology.

Opexa Therapeutics is initiating a phase IIb trial of a novel therapy that targets T-cells in patients with secondary progressive multiple sclerosis.

Taking more than 5 medications was associated with fatigue and memory problems in multiple sclerosis patients, a new study reports.

A new study in mice of the multiple sclerosis drug fingolimod (Gilenya) suggests the drug may be a new therapeutic target for a treatment of post-traumatic stress and other anxiety disorders.

Experts examine conflicting evidence regarding the continuation of disease-modifying therapy in patients with secondary progressive multiple sclerosis.

Session at the 2014 Annual Meeting of the Consortium of Multiple Sclerosis Centers debates whether the side effects associated with alemtuzumab, a novel anti-CD52 monoclonal antibody, might ultimately prevent its approval for the treatment of multiple sclerosis, despite evidence of clinical effectiveness.

Low rates of immunogenicity observed in study support the potential benefits of subcutaneous peginterferon beta-1a in the treatment of patients with relapsing-remitting multiple sclerosis.

The reductions in brain volume often seen in patients with chronic relapsing–remitting multiple sclerosis may be reduced by treatment with interferon beta-1a, though treatment may be affected by the patient's immunologic status.

Analysis of NARCOMS data showed that switching from natalizumab to fingolimod or injectable therapy was associated with an increased likelihood of reported disability progression.

Primary MS is characterized by neurodegeneration with neuroaxonal injury and diffuse inflammation; disease progression is linked with age. Effective management calls for symptom-specific medical management combined with wellness and health maintenance measures.

Although there are more treatment options than ever before available to patients and clinicians, new approaches are needed to treat acute exacerbations, as well as new options that can help meet the long-term goals of symptomatic management and rehabilitation.

Coping strategies based on enhanced mindfulness and a greater sense of agency can help patients improve their quality of life.

Medication selection should be driven by rational polypharmacy and take into account such factors as pain type, underlying symptoms, comorbidities, patient preference, and medication side effects.

Some studies have shown benefit in reducing pain and spasticity in patients with multiple sclerosis, but the data is mixed and can be highly subjective.